CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 179 enrolled
Drug / intervention
Flortaucipir F18 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02278367
NCT02278367Phase 2Completed
CompareCT.gov

Clinical Evaluation of 18F-AV-1451

Avid Radiopharmaceuticals·interventional·Posted Oct 30, 2014·Updated Sep 10, 2020

In Brief

A Phase 2 clinical trial evaluating Flortaucipir F18 and Brain PET scan for Alzheimer's Disease and 2 related conditions. Completed, enrolled 179 participants across 5 sites.

Detailed Summary

This study is designed to expand the database of flortaucipir F 18 safety and tau binding as measured by PET imaging and to provide standardized conditions for flortaucipir PET use, data collection and analysis to facilitate companion studies including, but not limited to, longitudinal studies of aging, depression, and traumatic brain injury.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease, Traumatic Brain Injury, Depression
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 30, 2014
Enrollment StartDec 1, 2014
Primary CompletionJun 26, 2019
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 11.7 years ago

Interventions

Flortaucipir F18drug

IV injection, 370 MBq (10 mCi), up to two doses

Brain PET scanprocedure

positron emission tomography (PET) scan of the brain